ArticleMolecular biology reports2025
Association of vitamin D receptor gene polymorphisms ApaI (rs7975232) and BsmI (rs1544410) with hepatocellular carcinoma susceptibility in Egyptian patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlobally, hepatocellular carcinoma (HCC) is a widespread cancer, with a rising incidence rate. Polymorphisms in the vitamin D receptor (VDR) gene were found to be related to the emergence of tumors in various organs.
aimThis study aimed to examine the association of the polymorphic VDR gene with HCC development in Egyptian patients.
methodsGene polymorphism analyses for VDR ApaI (rs7975232 A > C) and VDR BsmI (rs1544410 C > T) variants were performed for 100 patients with HCCs and 100 cancer-free controls, using the ARMS-PCR.
resultsRegarding ApaI (rs7975232 C > A) SNP, the percentage of variant C-allele was substantially higher in the HCC group than in the control (p < 0.001). Additionally, the ApaI (rs7975232) variant conferred a ~ 4-fold, 4-fold, and 5-fold risk for HCC, respectively, through the codominant (OR = 4.0), dominant (OR = 3.77), and allelic (OR = 5.44) models. Moreover, the dominant model of ApaI (rs7975232) showed a progressive disease state defined by the higher ascites grade, higher tumor grade, higher histopathological grade, larger tumor size, and more lymph node invasion compared to those carrying the wild-type genotype (p < 0.001, < 0.001, 0.002, 0.01, < 0.001 and 0.02, respectively). Conversely, the BsmI (rs1544410 C > T) SNP showed no significant association with the HCC incidence and outcome.
conclusionour study revealed that the ApaI (rs7975232 A > C) SNP conferred a considerable risk for HCC incidence and progression among Egyptian patients. The study is limited by the relatively small sample size and restriction to an Egyptian cohort; further studies in larger and ethnically diverse populations are required to confirm these findings.
Indexed as
Identifiers
41258623What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.